New endpoints for early-stage cancer are gaining regulatory traction
Read More
Read More
Read More
Error - something went wrong!
Let's start a conversation...
Thank you! We'll be in touch soon.
Learn how all stakeholders benefit when patients and their insights are at the heart of every aspect of clinical development.
Read More
In this infographic, we share five tips for building an effective reimbursement strategy for your oncology product.
Learn More
We have created this guide to simplify the terminology of real-world evidence (RWE) and outline some of the strategic options available.
Learn More
Discover three key considerations for crafting a successful genomic biomarker strategy in this article.
Read More
In this article, we summarize what we’ve learned and outline the top 10 rules for a successful DCT.
Read More
As a former regulator, Jorge shares his perspectives for the need of more faster endpoints to measure how targeted cancer drugs can benefit patients. He believes it can be created by combining two...
Learn More
Three risk management strategies for drug developers who wish to take full advantage of expedited pathways to achieve reimbursable innovation for the benefit of patients.
Watch Video
Key findings from a recent discussion with Parexel regulatory experts and the rare disease patient advocacy group Sara’s Cure.
Read More
Parexel experts discuss a recent project involving a Rare Disease Oncology therapeutic, in which our experts leveraged Real-world Evidence and FDA/Regulatory expertise to develop and execute a Synthet
Watch Video
Parexel’s Rosamund Round, Director, Patient Innovation Center and Amy McKee, Vice President, Regulatory Consulting Services sit down with Monica Theis, a breast cancer survivor and two-time clinical t
Watch Video
In this whitepaper, we address the unique variables, optimal timing, and immunogenic considerations for vaccinating individuals with cancer.
Read More
Among biotech companies, a primary concern is how to establish a clinical strategy for scientific and commercial success at the earliest stage. In that respect, regulatory considerations figure...
Learn More
Insights on regulatory and trial design considerations for drug development in oncology.
Learn More
Discover three key considerations for crafting a successful genomic biomarker strategy in this article.
Read More
Amy McKee, VP of Regulatory Consulting for Parexel and former Deputy Director of the FDA Oncology Center of Excellence, shares valuable insights about knowing when and how to engage with regulators.
Read More
In 2020, ASCO went virtual for the first time. While the format was different, one thing was clear: despite all that is happening in the world, there are still many patients in need. Todd Shuster,...
Learn More
Parexel’s Decentralized Clinical Trials represent an opportunity to rethink and refresh how research studies are conducted.
Read More
The global cancer drug market is set to maintain strong growth over the next decade due to factors such as environmental pollution, population aging, and poor lifestyles that leave...
Learn More